aldosterone and ADPKD studies

Research Excerpts

Excerpt	Relevance	Reference
" To study the function and regulation of the aquaporin-2 water channel (AQP2) and the epithelial sodium channel (ENaC) in autosomal dominant polycystic kidney disease (ADPKD), we measured urinary excretion of AQP2 (u-AQP2), the β-subunit of ENaC (u-ENaC(β)), cAMP (u-cAMP), and prostaglandin E(2) (u-PGE(2)); free water clearance (C(H2O)); fractional sodium excretion (FE(Na)); and plasma vasopressin (p-AVP), renin (p-Renin), angiotensin II (p-ANG II), aldosterone (p-Aldo), and atrial and brain natriuretic peptide (p-ANP, p-BNP) in patients with ADPKD and healthy controls during 24-h urine collection and after hypertonic saline infusion during high sodium intake (HS; 300 mmol sodium/day) and low sodium intake (LS; 30 mmol sodium/day)."	5.16	Urinary excretion of AQP2 and ENaC in autosomal dominant polycystic kidney disease during basal conditions and after a hypertonic saline infusion. ( Bech, JN; Graffe, CC; Lauridsen, TG; Pedersen, EB, 2012)
"Eight borderline hypertensive ADPKD patients with (near) normal renal function and seven matched healthy control subjects were investigated at three levels of daily dietary sodium intake: 150, 50 and 450 mmol."	1.29	Borderline hypertensive autosomal dominant polycystic kidney disease patients have enhanced production of renal dopamine. Normalization of renal haemodynamics by DOPA infusion. ( Barendregt, JN; Chang, PC; Florijn, KW; Muizert, Y, 1995)
"We studied young adults with autosomal dominant polycystic kidney disease (ADPKD) to determine the characteristics that precede renal impairment."	1.28	Renal, cardiovascular and hormonal characteristics of young adults with autosomal dominant polycystic kidney disease. ( Briggs, JD; Davies, DL; Dominiczak, AF; Fraser, R; Harrap, SB; Macnicol, AM; Watson, ML; Wright, AF, 1991)

Research

Studies (7)

Authors

Clinical Trials (2)

Trial Overview

Trial Outcomes

Albuminuria

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	4 (57.14)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (28.57)	24.3611
2020's	1 (14.29)	2.80

Authors	Studies
Malmberg, MH	1
Mose, FH	1
Pedersen, EB	2
Bech, JN	2
Torres, VE	1
Abebe, KZ	1
Chapman, AB	2
Schrier, RW	1
Braun, WE	1
Steinman, TI	1
Winklhofer, FT	1
Brosnahan, G	1
Czarnecki, PG	1
Hogan, MC	1
Miskulin, DC	1
Rahbari-Oskoui, FF	1
Grantham, JJ	1
Harris, PC	1
Flessner, MF	1
Moore, CG	1
Perrone, RD	1
Graffe, CC	1
Lauridsen, TG	1
Barendregt, JN	1
Florijn, KW	1
Muizert, Y	1
Chang, PC	1
Gabow, PA	1
Cerasola, G	1
Li Vecchi, M	1
Mulé, G	1
Cottone, S	1
Mangano, MT	1
Andronico, G	1
Contomo, A	1
Parrino, IA	1
Renda, F	1
Pavone, G	1
Scialabba, A	1
Harrap, SB	1
Davies, DL	1
Macnicol, AM	1
Dominiczak, AF	1
Fraser, R	1
Wright, AF	1
Watson, ML	1
Briggs, JD	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
The Kidneys Ability to Concentrate and Dilute Urine in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) or Other Cause of Chronic Renal Disease Compared to Healthy Volunteers[NCT04363554]		51 participants (Actual)	Interventional	2017-09-25	Completed
HALT Progression of Polycystic Kidney Disease Study B[NCT01885559]	Phase 3	486 participants (Actual)	Interventional	2006-01-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Annual percent change in 24 hour urine albumin, centrally processed. Data from multiple years were analyzed with the primary focus on the change over time for the measure (from the slope of the model). The measure presented is the average annual percent change across the 8 years. (NCT01885559)
Timeframe: up to 8 years (annually assessed)

Aldosterone

Intervention	annual percent change (Mean)
ACE-I + Placebo	7.5
ACE-I + ARB	7.3

Annual percent change in urinary aldosterone, centrally processed measure. Data from multiple years were analyzed with the primary focus on the change over time for the measure (from the slope for time from the model). The measure presented is the average annual percent change across the 8 years. (NCT01885559)
Timeframe: up at 8 years (annually assessed)

Back or Flank Pain

Intervention	annual percent change (Mean)
ACE-I + Placebo	-8.8
ACE-I + ARB	-10.2

Report of back or flank pain since the last visit (yes or no) (NCT01885559)
Timeframe: 48 months

Cardiovascular Hospitalizations

Intervention	percentage of participants at 48 months (Number)
ACE-I + Placebo	43
ACE-I + ARB	46

Cause-specific hospitalizations (cardiovascular) (NCT01885559)
Timeframe: up to 8 years

Hospitalizations

Number of Participants With 50% Reduction of Baseline eGFR, End Stage Renal Disease (ESRD, Initiation of Dialysis or Preemptive Transplant), or Death.

Intervention	events (Number)
ACE-I + Placebo	29
ACE-I + ARB	16

Intervention	events (Number)
ACE-I + Placebo	173
ACE-I + ARB	136

(NCT01885559)
Timeframe: Patients followed for 5-8 years with average of 6.5 years follow up

Quality of Life Mental Component Summary

Intervention	participants (Number)
ACE-I + Placebo	116
ACE-I + ARB	115

Short Form-36 Quality of Life Mental Component Summary ranges from 0 (worst possible outcome) to 100 (best possible outcome). Data from multiple years were analyzed with the primary focus on the change over time for the measure (from the slope for time from the model). The measure presented is the average annual change across the 8 years. (NCT01885559)
Timeframe: up to 8 years (annually assessed)

Quality of Life Physical Component Summary

Intervention	units on a scale per year (Mean)
ACE-I + Placebo	-0.031
ACE-I + ARB	-0.079

Short Form-36 Quality of Life Physical Component Summary ranges from 0 (worst possible outcome) to 100 (best possible outcome). Data from multiple years were analyzed with the primary focus on the change over time for the measure (from the slope for time from the model). The measure presented is the average annual change across the 8 years. (NCT01885559)
Timeframe: up to 8 years (annually assessed)

Article	Year
Angiotensin blockade in late autosomal dominant polycystic kidney disease. The New England journal of medicine, 2014, Dec-11, Volume: 371, Issue:24 Topics: Adolescent; Adult; Albuminuria; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Co	2014
Urinary excretion of AQP2 and ENaC in autosomal dominant polycystic kidney disease during basal conditions and after a hypertonic saline infusion. American journal of physiology. Renal physiology, 2012, Apr-15, Volume: 302, Issue:8 Topics: Adolescent; Adult; Aged; Aldosterone; Angiotensin II; Aquaporin 2; Atrial Natriuretic Factor; Chroni	2012

Article	Year
Urine concentration ability is reduced to the same degree in adult dominant polycystic kidney disease compared with other chronic kidney diseases in the same CKD-stage and lower THAN in healthy control subjects - a CASE control study. BMC nephrology, 2020, 08-31, Volume: 21, Issue:1 Topics: Adult; Aged; Aldosterone; Aquaporin 2; Case-Control Studies; Epithelial Sodium Channels; Female; Hum	2020
Borderline hypertensive autosomal dominant polycystic kidney disease patients have enhanced production of renal dopamine. Normalization of renal haemodynamics by DOPA infusion. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 1995, Volume: 10, Issue:8 Topics: Adult; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Dihydroxyphenylalanine	1995
Role of renin-angiotensin-aldosterone system and of sympathetic activity in arterial hypertension associated with autosomal dominant polycystic kidney disease. Contributions to nephrology, 1997, Volume: 122 Topics: Aldosterone; Blood Pressure; Catecholamines; Female; Humans; Hypertension; Hypertension, Renal; Male	1997
Renal, cardiovascular and hormonal characteristics of young adults with autosomal dominant polycystic kidney disease. Kidney international, 1991, Volume: 40, Issue:3 Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aldosterone; Atrial Natriuretic Factor; Dietary Proteins	1991

aldosterone and ADPKD